Constitutional Mismatch Repair-Deficiency Syndrome (CMMR-D) – a Case Report of a Family with Biallelic MSH6 Mutation

Czech version

Authors: D. Ilenčíková
Authors‘ workplace: II. detská klinika, LF UK a DFNsP Bratislava, Slovenská republika
Published in: Klin Onkol 2012; 25(Supplementum): 34-38

Overview

This work gives comprehensive information about new recessively inherited syndrome characterized by development of childhood malignancies. Behind this new described syndrome, called Constitutional mismatch repair-deficiency syndrome (CMMR-D), there are biallelic mutations in genes, which cause adult cancer syndrom termed Lynch syndrom (Hereditary non-polyposis cancer syndrom-HNPCC) if they are heterozygous mutations. Biallelic germline mutations of genes MLH1, MSH2, MSH6 and PMS2 in CMMR-D are characterized by increased risk of hematological malignancies, atypical brain tumors and early onset of colorectal cancers. An accompanying manifestation of the disease are skin spots with diffuse margins and irregular pigmentation reminiscent of Café au lait spots of NF1. This paper reports a case of a family with CMMR-D caused by novel homozygous MSH6 mutations leading to gliomatosis cerebri, T-ALL in an 11-year-old female and glioblastoma multiforme in her 10-year-old brother, both with rapid progression of the diseases. A literature review of brain tumors in CMMR-D families shows that they are treatment-resistant and lead to early death. Therefore, this work highlights the importance of early identification of patients with CMMR-D syndrome – in terms of initiation of a screening program for early detection of malignancies as well as early surgical intervention.

Key words:
constitutional mismatch repair-deficiency syndrome (CMMR-D) – MSH6 – high-grade brain tumors – childhood T-NHL

The author declares he has no potential conflicts of interest concerning drugs, pruducts, or services used in the study.

The Editorial board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
24. 4. 2012

Accepted:
25. 6. 2012

Sources

1. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7(5): 335–346.

2. Wimmer K, Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica 2010; 95(5): 699–701.

3. Gardès P, Forveille M, Alyanakian MA et al. Human MSH6 deficiency is associated with impaired antibody maturation. J Immunol 2012; 188(4): 2023–2029.

4. Ilenčíková D, Bartošová Z, Babál P. Lynchov syndróm – novinky v diagnostike a liečbe. Onkologia 2010; 5(2): 70–76.

5. Ricciardone MD, Ozcelik T, Cevher B et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 1999; 59(2): 290–293.

6. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer 2005; 4(4): 323–333.

7. Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair: is it time for Lynch III? Clin Genet 2007; 71(6): 499–500.

8. Krüger S, Kinzel M, Walldorf D et al. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. Eur J Hum Genet 2008; 16(1): 62–72.

9. Scott RH, Mansour S, Pritchard-Jones K et al. Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 2007; 4(2): 130–139.

10. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrom: have we so far seen only the tip of an iceberg? Hum Genet 2008; 124(2): 105–122.

11. Yip S, Miao J, Cahill DP et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009; 15(14): 4622–4629.

12. Ripperger T, Beger C, Rahner N et al. Constitutional mismatch repair deficiency and childhood leukemia/lymphoma – report on a novel biallelic MSH6 mutation. Haematologica 2010; 95(5): 841–844.

13. Ollikainen M, Abdel-Rahman WM, Moisio AL et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 2005; 23(21): 4609–4616.

14. Peters A, Born H, Ettinger R et al. Compound heterozygosity for MSH6 mutations in a pediatric lymphoma patient. J Pediatr Hematol Oncol 2009; 31(2): 113–115.

15. Ostergaard JR, Sunde L, Okkels H. Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6. Am J Med Genet 2005; 139A(2): 96–105.

16. Etzler J, Peyrl A, Zatkova A et al. RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. Hum Mutat 2008; 29(2): 299–305.

17. Rahner N, Höefler G, Högenauer C et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. Am J Med Genet A 2008; 146A(10): 1314–1319.

18. Scott RH, Mansour S, Pritchard-Jones K et al. Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 2007; 4(2): 130–134.

19. Auclair J, Leroux D, Desseigne F et al. Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Hum Mutat 2007; 28(11): 1084–1090.

20. Ilencikova D, Sejnova D, Jindova J et al. High-grade brain tumors in siblings with biallelic MSH6 mutations. Pediatric Blood Cancer 2011; 57(6): 1067–1070.

21. Vasen HF, Möeslein G, Alonso O et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44(6): 353–262.

22. Ďurovčíková D. Neurofibromatosis typ 1 ochorenie multidisciplinárneho charakteru. Revue Med Prax 2008; 6(4): 10–12.

23. Messiaen L, Wimmer K. NF1 Mutational Spectrum. In: Kaufmann D (ed). Neurofibromatoses. Monogr Hum Genet Basel Karger 2008; 16: 63–77.

24. Allanson JE, Upadhyava M, Watson GH et al. Watson syndrome: is it a subtype of type 1 neurofibromatosis? J Med Genet 1991; 28(11): 752–756.

25. Brems H, Chmara M, Sahbatou M et al. Germline loss-of-function mutations in SPRED1 cause neurofibromatosis 1-like phenotype. Nat Genet 2007; 39(9): 1120–1126.

26. Hlavatá A, Rybárová A, Košťálová Ľ et al. Dlhodobé komplexné sledovanie detí s neurofibromatózou v detskom veku. Pediatr Prax 2009; 10(2): 75–80.

27. Ilenčíková D, Ďurovčíková D, Rybárová A et al. Nový syndróm malignity v diferenciálnej diagnostike s neurofibromatózou 1 a jej podobným chorobám. Lek Obzory 2009; 57(5): 221–227.